Rayno Biobeat #2…Good Value in Large Cap Biopharmaceuticals

Merck has become a major biotech player with their Keytruda lung cancer drug, a strong Phase II,III pipeline and 6% Q3 sales growth. MRK stock leads the group up 11.36% YTD despite the October downdraft.